RENO, NV--(Marketwire - July 11, 2008) - MabCure Inc. (OTCBB: MBCI) (the “Company” or “MabCure”). The Company is pleased to announce the closing, today, of the acquisition of a proprietary platform technology for the rapid and efficient generation of monoclonal antibodies (MAbs). In its first application the Company will be focusing on creating novel MAbs against cancer markers (the “MAbs Technology”).
